Third Rock Ventures has closed its debut fund with $378 million in capital commitments. The Boston-based firm will focus on early-stage life sciences opportunities. It was founded by four ex-Millennium Pharma executives, including former Millennium CEO Mark Levin, who had been a partner with Mayfield Fund until 1994. www.thirdrockventures.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.